Celldex Therapeutics, Inc. (CLDX)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
CLDX Insider Trading Activity
CLDX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $308,430 | 1 | 8 |
Sells | $12,092,085 | 11 | 92 |
Related Transactions
| Marucci Anthony S | PRESIDENT & CEO | 1 | $308,430 | 0 | $0 | $308,430 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL | 0 | $0 | 1 | $269,002 | $-269,002 |
| Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | 0 | $0 | 1 | $703,334 | $-703,334 |
| Wright Richard M. | SR. VP & CCO | 0 | $0 | 1 | $1.58M | $-1.58M |
| Young Diane C. | SVP, CHIEF MEDICAL OFFICER | 0 | $0 | 1 | $1.59M | $-1.59M |
| Martin Samuel Bates | SVP AND CFO | 0 | $0 | 2 | $1.8M | $-1.8M |
| Crowley Elizabeth | SR. VP & CPDO | 0 | $0 | 3 | $2.87M | $-2.87M |
| Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | 0 | $0 | 2 | $3.28M | $-3.28M |
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Insider Activity of Celldex Therapeutics, Inc.
Over the last 12 months, insiders at Celldex Therapeutics, Inc. have bought $308,430 and sold $12.09M worth of Celldex Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Celldex Therapeutics, Inc. have bought $153,972 and sold $5.35M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Marucci Anthony S (PRESIDENT & CEO) — $308,430.
The last purchase of 11,500 shares for transaction amount of $308,430 was made by Marucci Anthony S (PRESIDENT & CEO) on 2024‑11‑11.
List of Insider Buy and Sell Transactions, Celldex Therapeutics, Inc.
| 2024-11-11 | Marucci Anthony S | PRESIDENT & CEO | 11,500 0.0178% | $26.82 | $308,430 | -6.37% | ||
| 2024-06-14 | Sale | Martin Samuel Bates | SVP AND CFO | 17,172 0.0259% | $35.42 | $608,315 | -19.44% | |
| 2024-06-14 | Sale | Crowley Elizabeth | SR. VP & CPDO | 30,000 0.0446% | $34.87 | $1.05M | -19.44% | |
| 2024-06-07 | Sale | Crowley Elizabeth | SR. VP & CPDO | 15,000 0.0226% | $35.06 | $525,873 | -20.24% | |
| 2024-06-07 | Sale | Young Diane C. | SVP, CHIEF MEDICAL OFFICER | 45,000 0.0682% | $35.26 | $1.59M | -20.24% | |
| 2024-06-03 | Sale | Jimenez Freddy A. | SVP & GENERAL COUNSEL | 8,006 0.0122% | $33.60 | $269,002 | -14.34% | |
| 2024-06-03 | Sale | Wright Richard M. | SR. VP & CCO | 46,844 0.0716% | $33.72 | $1.58M | -14.34% | |
| 2024-06-03 | Sale | Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | 58,369 0.089% | $33.65 | $1.96M | -14.34% | |
| 2024-05-30 | Sale | Martin Samuel Bates | SVP AND CFO | 35,000 0.0538% | $34.05 | $1.19M | -14.66% | |
| 2024-05-30 | Sale | Crowley Elizabeth | SR. VP & CPDO | 38,597 0.0586% | $33.64 | $1.3M | -14.66% | |
| 2024-05-30 | Sale | Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | 38,719 0.0595% | $34.07 | $1.32M | -14.66% | |
| 2024-05-30 | Sale | Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | 20,853 0.0317% | $33.73 | $703,334 | -14.66% | |
| 2022-12-07 | Sale | KELER TIBOR | EXECUTIVE VP & CSO | 16,860 0.0356% | $36.93 | $622,611 | -7.66% | |
| 2022-08-17 | Sale | Young Diane C. | SVP, CHIEF MEDICAL OFFICER | 19,000 0.0411% | $37.30 | $708,715 | -4.79% | |
| 2022-08-17 | Sale | Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | 1,355 0.0029% | $36.38 | $49,289 | -4.79% | |
| 2022-08-15 | Sale | Marucci Anthony S | PRESIDENT & CEO | 120,000 0.2564% | $37.66 | $4.52M | -6.57% | |
| 2022-08-15 | Sale | Wright Richard M. | SR. VP & CCO | 15,328 0.0328% | $37.71 | $578,048 | -6.57% | |
| 2022-08-11 | Sale | Martin Samuel Bates | SVP AND CFO | 14,261 0.0324% | $36.76 | $524,304 | +1.85% | |
| 2021-12-23 | Sale | Martin Samuel Bates | SVP and CFO | 9,500 0.0203% | $42.00 | $399,000 | -25.17% | |
| 2021-12-08 | Sale | Heath-Chiozzi Margo | SVP of Regulatory Affairs | 600 0.0013% | $40.00 | $24,000 | -20.89% |
Insider Historical Profitability
| Marucci Anthony S | PRESIDENT & CEO | 40284 0.0607% | $822,599.28 | 6 | 1 | +138.14% |
| Martin Samuel Bates | SVP AND CFO | 28125 0.0424% | $574,312.50 | 1 | 6 | +500.67% |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL | 25924 0.0391% | $529,368.08 | 1 | 1 | <0.0001% |
| Wright Richard M. | SR. VP & CCO | 20833 0.0314% | $425,409.86 | 0 | 3 | |
| Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | 13383 0.0202% | $273,280.86 | 1 | 4 | +500.67% |
| Crowley Elizabeth | SR. VP & CPDO | 9074 0.0137% | $185,291.08 | 0 | 5 | |
| Young Diane C. | SVP, CHIEF MEDICAL OFFICER | 2115 0.0032% | $43,188.30 | 1 | 3 | +105.94% |
| Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | 1860 0.0028% | $37,981.20 | 1 | 4 | +275.1% |
| MEDAREX INC | 10 percent owner | 2960848 4.4602% | $60.46M | 0 | 2 | |
| RYAN UNA S | President & CEO | 898713 1.3538% | $18.35M | 2 | 0 | |
| SEARS PETER A | director | 72739 0.1096% | $1.49M | 1 | 0 | |
| ELLBERGER LARRY | director | 53500 0.0806% | $1.09M | 5 | 1 | +3.43% |
| PAREKH RAJESH R | director | 40000 0.0603% | $816,800.00 | 1 | 3 | <0.0001% |
| WARD J BARRIE | director | 35774 0.0539% | $730,505.08 | 0 | 1 | |
| CATLIN AVERY W | Sr. VP & CFO | 35109 0.0529% | $716,925.78 | 5 | 3 | +20.69% |
| PENNER HARRY JR | director | 13416 0.0202% | $273,954.72 | 1 | 1 | +13.16% |
| LIPTON KAREN SHOOS | director | 13333 0.0201% | $272,259.86 | 1 | 1 | +3.2% |
| MARINO JAMES J | director | 12704 0.0191% | $259,415.68 | 2 | 0 | +231.19% |
| KELER TIBOR | EXECUTIVE VP & CSO | 7357 0.0111% | $150,229.94 | 5 | 1 | +101.05% |
| KYLE FREDERICK W | director | 7000 0.0105% | $142,940.00 | 0 | 2 | |
| SCHALLER CHARLES R | director | 5000 0.0075% | $102,100.00 | 4 | 0 | +1.11% |
| SHANNON TIMOTHY M | director | 3200 0.0048% | $65,344.00 | 1 | 0 | +11.03% |
| Davis Thomas Andrew | Sr. VP & CMO | 1489 0.0022% | $30,405.38 | 1 | 0 | +3.2% |
Historical Insider Profitability vs. Competitors
$8,217,280 | 112 | 46.33% | $1.29B | |
$831,902,292 | 108 | 9.34% | $1.58B | |
$20,297,544 | 73 | 103.06% | $1.61B | |
$54,590,806 | 65 | 21.84% | $1.23B | |
$1,101,324,300 | 58 | 37.37% | $1.3B | |
$11,583,737 | 45 | 49.75% | $1.75B | |
$100,002,191 | 42 | 21.48% | $1.22B | |
$309,951,506 | 30 | 32.56% | $1.24B | |
Celldex Therapeutics, Inc. (CLDX) | $1,295,059 | 29 | 102.78% | $1.36B |
$7,598,498 | 27 | 34.68% | $1.17B | |
$169,638,586 | 22 | 30.82% | $1.18B | |
$43,198,628 | 12 | -0.10% | $1.3B | |
$137,013,690 | 11 | 26.62% | $1.73B | |
$45,445,266 | 9 | -24.96% | $1.63B | |
$107,703,099 | 7 | 29.71% | $1.57B | |
$91,325,021 | 6 | 1.83% | $1.36B | |
$8,503,480 | 3 | 132.88% | $1.15B | |
$142,493,653 | 3 | 4.30% | $1.64B | |
$10,000,009 | 1 | 100.92% | $1.76B |
CLDX Institutional Investors: Active Positions
| Increased Positions | 101 | +51.27% | 13M | +18.03% |
| Decreased Positions | 85 | -43.15% | 11M | -15.43% |
| New Positions | 35 | New | 3M | New |
| Sold Out Positions | 38 | Sold Out | 6M | Sold Out |
| Total Postitions | 213 | +8.12% | 74M | +2.59% |
CLDX Ownership Change vs Market
Institutional Investor Ownership
| Wellington Management Group Llp | $184,633.00 | 13.6% | 8.98M | -267,766 | -2.9% | 2024-12-31 |
| Blackrock, Inc. | $112,737.00 | 8.3% | 5.48M | +600,650 | +12.31% | 2024-12-31 |
| Kynam Capital Management, Lp | $104,171.00 | 7.67% | 5.06M | +2M | +46.42% | 2024-12-31 |
| Fmr Llc | $99,922.00 | 7.36% | 4.86M | -1M | -19.37% | 2024-12-31 |
| Vanguard Group Inc | $79,853.00 | 5.88% | 3.88M | +12,213 | +0.32% | 2024-12-31 |
| Eventide Asset Management, Llc | $77,205.00 | 5.69% | 3.75M | +421,255 | +12.64% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $73,170.00 | 5.39% | 3.56M | +676,771 | +23.5% | 2024-12-31 |
| State Street Corp | $66,543.00 | 4.9% | 3.23M | +749,805 | +30.17% | 2024-12-31 |
| Bellevue Group Ag | $63,183.00 | 4.65% | 3.07M | 0 | 0% | 2024-12-31 |
| Point72 Asset Management, L.P. | $51,754.00 | 3.81% | 2.52M | +947,264 | +60.38% | 2024-12-31 |